Clinical trial • Phase I • Oncology
eVim vaccine CVX1 for Muscle-invasive bladder cancer | Renal cell carcinoma | Metastatic solid cancer
Phase I trial of eVim vaccine CVX1 for Muscle-invasive bladder cancer | Renal cell carcinoma | Metastatic solid cancer. 83 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Muscle-invasive bladder cancer | Renal cell carcinoma | Metastatic solid cancer
- Trial Stage
- Phase I
- Drug Modality
- Vaccine | Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 10-11-2025
- First CTIS Authorization Date
- 29-01-2026
Trial design
Phase I trial across 4 sites in Netherlands.
- Target Sample Size
- 83
Eligibility
Recruits 83 No vulnerable populations selected; no details on consent or assent provided..
- Vulnerable Population
- No vulnerable populations selected; no details on consent or assent provided.
Recruitment
- Planned Sample Size
- 83
- Recruitment Window Months
- 35
- Consent Approach
- No details on informed consent or assent processes provided in the record.
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 83
Netherlands
- Earliest CTIS Part Ii Submission Date
- 13-01-2026
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 91
- Number Of Sites
- 4
- Number Of Participants
- 83
Sites
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Medical Oncology
- Principal Investigator Name
- Adriaan Bins
- Principal Investigator Email
- a.d.bins@amsterdamumc.nl
- Contact Person Name
- Adriaan Bins
- Contact Person Email
- a.d.bins@amsterdamumc.nl
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Medical Oncology
- Principal Investigator Name
- Debbie Robbrecht
- Principal Investigator Email
- d.robbrecht@erasmusmc.nl
- Contact Person Name
- Debbie Robbrecht
- Contact Person Email
- d.robbrecht@erasmusmc.nl
- Site Name
- Netherlands Cancer Institute
- Department Name
- Medical Oncology
- Principal Investigator Name
- Tim Schutte
- Principal Investigator Email
- t.schutte@nki.nl
- Contact Person Name
- Tim Schutte
- Contact Person Email
- t.schutte@nki.nl
- Site Name
- Leids Universitair Medisch Centrum (LUMC)
- Department Name
- Medical Oncology
- Principal Investigator Name
- Tom van der Hulle
- Principal Investigator Email
- t.van_der_hulle@lumc.nl
- Contact Person Name
- Tom van der Hulle
- Contact Person Email
- t.van_der_hulle@lumc.nl
Sponsor
Primary sponsor
- Full Name
- CimCure B.V.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- eVim vaccine CVX1
- Modality
- Vaccine
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)